Skip to main content

Table 1 Demographic and clinical characteristics

From: In-vivo assessment of the morphology and hemodynamic functions of the BioValsalva™ composite valve-conduit graft using cardiac magnetic resonance imaging and computational modelling technology

Variables

Control (n = 2)

Patients (n = 4)

P-value

Male [n (%)]

2 (100%)

4 (100%)

_

Age (years)

62 ± 4

66 ± 5

0.21

Age range (years)

55- 72

59- 78

 

White Caucasian [n (%)]

2 (100%)

4 (100%)

_

DM [n (%)]

0 (0%)

0 (0%)

_

Hypertension [n (%)]

0 (0%)

3 (75%)

0.4

Statin treatment [n (%)]

0 (0%)

3 (75%)

0.4

BMI (kg/m2)

30 ± 1.8

28.3 ± 2.8

0.35

Heart Rate

68 ± 13

64 ± 7

0.64

SBP (mmHg)

131 ± 1

129 ± 8

0.48

DBP (mmHg)

79 ± 1

68 ± 14

0.35

PP (mmHg)

53 ± 2

61 ± 21

0.64

MAP (mmHg)

96 ± 1

88 ± 7

0.35

Height (cm)

183 ± 5

176 ± 3

0.06

Weight (kg)

101 ± 11

90 ± 12

0.16

PVD [n (%)]

0 (0%)

0 (0%)

_

Marfan’s syndrome

0 (0%)

0 (0%)

_

Bicuspid aortic valve

0 (0%)

1 (25%)

_

NYHA (pre-op.) [n (%)]

  

0.46

 Class I

2 (100%)

2 (50%)

 

 Class II

0 (0%)

2 (50%)

 

NYHA (post-op.) [n (%)]

  

_

 Class I

2 (100%)

4 (100%)

 

 Class II

0 (0%)

0 (0%)

 

Operative characteristics

   

Indication for surgery, dilated aortic root and

   

 Aortic stenosis

 

1 (25%)

 

 Aortic regurgitation

 

2 (50%)

 

 Aortic stenosis and regurgitation

 

1 (25%)

 

Elective

 

4 (100%)

 

CPB time (minutes)

 

190 ± 51

 

Inotropes [n (%)]

 

4 (100%)

 

Atrial Fibrillation [n (%)]

 

4 (100%)

 

Blood products

 

4 (100%)

 

> 24 intubation

 

2 (50%)

 

Hospital stay (days)

 

10.5 ± 2.6

 
  1. Values are shown as n (%) for categorical variables and as mean ± SD for continuous variables. No statistics are computed. DM: diabetes mellitus; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MAP: mean arterial blood pressure; PVD: peripheral vascular disease; NYHA: New York Heart Association; CPB: cardiopulmonary bypass.